Exhibit 10.2

VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE BOSTON, MA 02210
TEL. 617.341.6100

March 28, 2019

Charles F. Wagner, Jr.
22 Quarry Road
Medfield, MA 02052

RE:    Change of Control Agreement

Dear Mr. Wagner:

You are a key member of the senior management team of Vertex Pharmaceuticals
Incorporated (the “Company”). As a result, the Company would like to provide you
with the following “change of control” benefits to help ensure that if the
Company becomes involved in a “change of control” transaction, there will be no
distraction from your attention to the needs of the Company.

I.
Definitions. For the purposes of this Change of Control Agreement (this
“Agreement”), capitalized terms shall have the following meanings:

1.
“Cause” shall mean:

(a)
your conviction of a crime involving moral turpitude;

(b)
your willful refusal or failure to follow a lawful directive or instruction of
the Company’s Board of Directors or the individual(s) to whom you report,
provided that you receive prior written notice of the directive(s) or
instruction(s) that you failed to follow, and provided further that the Company,
in good faith, gives you 30 days to correct such failure and further provided
that if you correct the failure(s), any termination of your employment on
account of such failure shall not be treated for purposes of this Agreement as a
termination of employment for “Cause”;

(c)
in carrying out your duties you commit (i) willful gross negligence, or
(ii) willful gross misconduct, resulting in either case in material harm to the
Company, unless such act, or failure to act, was believed by you, in good faith,
to be in the best interests of the Company; or

(d)
your violation of the Company’s policies made known to you regarding
confidentiality, securities trading or inside information.

2.
“Change of Control” shall mean that:

(a)
any “person” or “group” as such terms are used in Sections 13(d) and 14(d)(2) of
the Securities Exchange Act of 1934 (the “Act”), becomes a beneficial owner, as
such term is used in Rule 13d-3 promulgated under the Act, of securities of the
Company representing more than 50% of the combined voting power of the
outstanding securities of the Company having the right to vote in the election
of directors; or

(b)
all or substantially all the business or assets of the Company are sold or
disposed of, or the Company or a subsidiary of the Company combines with another
company pursuant to a merger,

--------------------------------------------------------------------------------

consolidation, or other similar transaction, other than (i) a transaction solely
for the purpose of reincorporating the Company or one of its subsidiaries in a
different jurisdiction or recapitalizing or reclassifying the Company’s stock;
or (ii) a merger or consolidation in which the shareholders of the Company
immediately prior to such merger or consolidation continue to own at least a
majority of the outstanding voting securities of the Company or the surviving
entity immediately after the merger or consolidation.

3.
“Code” shall mean the Internal Revenue Code of 1986, as amended.

4.
“Disability” shall mean a disability as determined under the Company's long-term
disability plan or program in effect at the time the disability first occurs, or
if no such plan or program exists at the time of disability, then a “disability”
as defined Section 22(e)(3) of the Code.

5.
“Good Reason” shall mean one of the following events has occurred without your
consent:

(a)
You suffer a material reduction in the authorities, duties or job title and
responsibilities associated with your position as Executive Vice President,
Chief Financial Officer for the Company as of the date hereof;

(b)
your annual base salary is decreased;

(c)
the office to which you are assigned is relocated to a place 35 or more miles
away; or

(d)
following a Change of Control, the Company’s successor fails to assume the
Company’s rights and obligations under this Agreement;

provided that Good Reason shall not exist unless and until within 30 days after
the event giving rise to Good Reason under (a), (b), (c) or (d) above has
occurred, you deliver a written termination notice to the Company stating that
an event giving rise to Good Reason has occurred and identifying with reasonable
detail the event that you assert constitutes Good Reason under (a), (b), (c) or
(d) above and the Company fails or refuses to cure or eliminate the event giving
rise to Good Reason on or within 30 days after receiving your notice. To avoid
doubt, the termination of your employment will become effective at the close of
business on the thirtieth day after the Company receives your termination
notice, unless the Company cures or eliminates the event giving rise to Good
Reason prior to such time.

6.
“Termination Date” shall mean the last day of your employment with the Company.

I.
Severance Benefits upon Change of Control. If:

(A)
your employment is terminated by the Company (except for termination for Cause
or due to a Disability or death) and the Termination Date is within 90 days
prior to a Change of Control or within 12 months after a Change of Control; or

(B)
you, of your own initiative, (i) terminate your employment for Good Reason (in
accordance with the notice and cure provisions set forth in Section I.5 above)
and (ii) the event giving rise to Good Reason occurs within 90 days prior to a
Change of Control or within 12 months after a Change of Control;

then, you shall receive the following benefits:

1.
Severance Payment. In exchange for your execution within 60 days of the
Termination Date of a general release, in a form satisfactory to the Company, of
all claims against the Company, its subsidiaries, and its and their officers,
directors and representatives, that becomes enforceable and irrevocable within
such 60-day period, the Company shall make a cash payment (the “Severance
Payment”) to you in an amount equal to:

(a)
(i) your annual base salary (provided, however, that if you terminate your
employment for Good Reason based on a reduction in your annual base salary, then
the annual base salary to

--------------------------------------------------------------------------------

be used in calculating the Severance Payment shall be your annual base salary in
effect immediately prior to such reduction in annual base salary) plus your
target bonus under any bonus program applicable to you for the year in which the
Termination Date occurs; plus
    
(b)
a prorata portion of your target bonus for the portion of the year in which the
Termination Date occurs under any bonus program applicable to you; plus

(c)
all other cash incentive compensation awards earned by you but not paid prior to
the Termination Date; provided that, if a fiscal year has been completed and the
incentive award for such fiscal year has not been determined, the incentive
compensation for such completed fiscal year shall equal the target bonus for
such fiscal year.

Except with respect to any portion of the Severance Payment that is delayed as
set forth in this paragraph, the Severance Payment shall be made in cash within
ten days after the execution by you of the general release referred to above and
expiration without revocation of any applicable revocation periods under such
general release (or, if the Change of Control resulting in your becoming
entitled to such benefits occurs after such execution and expiration, within ten
days after the Change of Control), provided that, if the 60-day period during
which the general release is required to become effective and irrevocable begins
in one calendar year and ends in another calendar year, the Severance Payment
shall not be made before the first day of the second calendar year.

If you are a “specified employee” (as defined below) on the Termination Date,
the commencement of the delivery of any such payments that constitute
nonqualified deferred compensation payable upon a “separation from service” (as
defined below) will be delayed until the first business day that is more than
six months after your Termination Date. The determination of whether, and the
extent to which, any of the payments to be made to you hereunder are
nonqualified deferred compensation shall be made after the application of all
applicable exclusions, including those set forth under Treasury Reg. §
1.409A-1(b)(9) and Treasury Reg. § 1.409A-1(a)(5). For purposes of this
Agreement, to the extent required to ensure compliance with Section 409A of the
Code, all references to “termination of employment” and correlative phrases
shall be construed to require a “separation from service” (as defined in
Treasury Reg. §1.409A-1(h) after giving effect to the presumptions contained
therein), and the term “specified employee” means an individual determined by
the Company to be a specified employee under Treasury Reg. §1.409A-1(i). Each
payment made under this Agreement shall be treated as a separate payment and the
right to a series of installment payments under this Agreement is to be treated
as a right to a series of separate payments. Your right to payment or
reimbursement for any expenses hereunder that would constitute nonqualified
deferred compensation subject to Section 409A will be subject to the following
additional rules: (i) the amount of expenses eligible for payment or
reimbursement during any calendar year shall not affect the expenses eligible
for payment or reimbursement in any other calendar year, (ii) payment or
reimbursement shall be made not later than December 31 of the calendar year
following the calendar year in which the expense or payment was incurred, and
(iii) the right to payment or reimbursement shall not be subject to liquidation
or exchange for any other benefit.

2.
Accelerated Vesting.

(a)
On the Termination Date, stock options for the purchase of the Company’s
securities held by you as of the Termination Date and not then exercisable shall
immediately become exercisable in full. The options to which this accelerated
vesting applies shall remain exercisable until the earlier of (a) the end of the
90-day period immediately following the later of (i) the Termination Date or
(ii) the date of the Change of Control and (b) the date the stock option(s)
would otherwise expire; and

--------------------------------------------------------------------------------

(b)
On the Termination Date, each outstanding restricted stock unit grant shall be
accelerated and the Shares shall be delivered to you within two business days
(subject to (i) your making satisfactory arrangements with the Company providing
for the payment to the Company of all required withholding taxes and (ii) with
the number of shares subject to the restricted stock unit grants that contain
performance criteria vesting at target or based on earned shares as set forth in
the applicable restricted stock grant). 1-year financial performance stock unit
awards vest as to target shares until the initial vesting date and based on
earned performance shares thereafter. 3-year non-financial performance stock
unit awards vest as to target shares.

Notwithstanding anything to the contrary in this Agreement, the terms of any
option agreement or restricted stock unit agreement shall govern the
acceleration, if any, of vesting or lapsing of the Company’s repurchase rights
and period of exercisability of such awards, as applicable, except to the extent
that the terms of this Agreement are more favorable to you.

3.
Continued Insurance Coverage. If COBRA coverage is elected by you, the Company
shall pay the cost of insurance continuation premiums on your behalf (whether or
not covered by COBRA) to continue standard medical, dental and life insurance
coverage for you (or the cash equivalent of same if you are ineligible for
continued coverage) until the earlier of (i) the date 12 months after the
Termination Date or (ii) the date you begin receiving substantially equivalent
coverage and benefits through a subsequent employer.

4.
No Mitigation. You shall not be required to mitigate the amount of the Severance
Payment or any other benefit provided under this Agreement by seeking other
employment or otherwise, nor shall the amount of any payment or benefit provided
for in this Agreement be reduced (except as provided in Article II Section
3(ii)) by any compensation earned by you as the result of other employment, by
retirement benefits, or be offset against any amount claimed to be owed by you
to the Company or otherwise (except for any required withholding taxes);
provided, that if the Company makes any other severance payments to you under
any other program or agreement, such amounts shall be offset against the
payments the Company is obligated to make pursuant to this Agreement.

II.
Miscellaneous.

1.
Employee’s Obligations. Upon the termination of employment, you shall promptly
deliver to the Company all property of the Company and all material documents,
statistics, account records, programs and other similar tangible items which may
by in your possession or under your control and which relate in a material way
to the business or affairs of the Company or its subsidiaries, and no copies of
any such documents or any part thereof shall be retained by you.

2.
Entire Agreement. This Agreement, the “Employment Agreement” and the “Employee
Non-Disclosure, Non-Competition & Intellectual Property Assignment Agreement”
executed by you covers the entire understanding of the parties as to the subject
matter hereof, superseding all prior understandings and agreements related
hereto. No modification or amendment of the terms and conditions of this
Agreement shall be effective unless in writing and signed by the parties or
their respective duly authorized agents, provided, however, that the Company
may, without your consent, unilaterally adopt amendments that may be required so
that this Agreement continues to comply with applicable law or regulation,
including without limitation Section 409A of the Code, provided such amendments
do not adversely affect the benefits to be provided to you under Section II of
this Agreement. In no event shall the Company have any liability relating to the
failure or alleged failure of any payment or benefit under this Agreement to
comply with or be exempt from, the requirements of Section 409A.

3.
Governing Law. This Agreement shall be governed by the laws of The Commonwealth
of Massachusetts, as applied to contracts entered into and performed entirely in
Massachusetts by Massachusetts residents.

--------------------------------------------------------------------------------

4.
Successors and Assigns. This Agreement may be assigned by the Company upon a
sale, transfer or reorganization of the Company. Upon a Change of Control, the
Company shall require the successor to assume the Company’s rights and
obligations under this Agreement. The Company’s failure to do so shall
constitute Good Reason and a material breach of this Agreement. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
successors, permitted assigns, legal representatives and heirs.

Kindly indicate your acceptance of the foregoing by signing and dating this
Agreement as noted below, and returning one fully executed original to my
attention.

Very truly yours,

Vertex Pharmaceuticals Incorporated

By: /s/ Michael Parini                        
Name: Michael Parini
Title: Executive Vice President, Chief Legal and Administrative Officer

ACCEPTED AND AGREED:

/s/ Charles F. Wagner, Jr.
    

Charles F. Wagner, Jr.